These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38040863)

  • 1. Targeted identification of risk and treatment of diabetic kidney disease.
    Glastras SJ; Pollock CA
    Nat Rev Nephrol; 2024 Feb; 20(2):75-76. PubMed ID: 38040863
    [No Abstract]   [Full Text] [Related]  

  • 2. Progression of diabetic kidney disease: Who is at risk?
    Jamale T
    J Postgrad Med; 2020; 66(4):182-183. PubMed ID: 33109780
    [No Abstract]   [Full Text] [Related]  

  • 3. Combat diabetic nephropathy: from pathogenesis to treatment.
    Gohda T; Mima A; Moon JY; Kanasaki K
    J Diabetes Res; 2014; 2014():207140. PubMed ID: 24741570
    [No Abstract]   [Full Text] [Related]  

  • 4. Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease.
    Cherney DZ; Tuttle KR
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):444-446. PubMed ID: 32149722
    [No Abstract]   [Full Text] [Related]  

  • 5. [Diabetes mellitus, hypertension and kidney].
    Monhart V
    Vnitr Lek; 2008 May; 54(5):499-504, 507. PubMed ID: 18630636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogens and the diabetic kidney.
    Maric C; Sullivan S
    Gend Med; 2008; 5 Suppl A(Suppl A):S103-13. PubMed ID: 18395675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing the development and progression of diabetic kidney disease: Where do we stand?
    Zagkotsis G; Markou M; Paschou E; Papanikolaou P; Sabanis N
    Diabetes Metab Syndr; 2018 Jul; 12(4):585-590. PubMed ID: 29602760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms and therapeutic targets for diabetic kidney disease.
    Tuttle KR; Agarwal R; Alpers CE; Bakris GL; Brosius FC; Kolkhof P; Uribarri J
    Kidney Int; 2022 Aug; 102(2):248-260. PubMed ID: 35661785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in the Early Detection of Risk of End-Stage Kidney Disease in Diabetes at Last?
    Berg AH; Sacks DB
    Clin Chem; 2023 Jul; 69(7):673-675. PubMed ID: 36762398
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetic nephropathy in patients with type II diabetes.
    Lewis JB
    Geriatr Nephrol Urol; 1999; 9(3):167-75. PubMed ID: 10701139
    [No Abstract]   [Full Text] [Related]  

  • 11. Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
    Kanda E; Nangaku M
    Kidney Int; 2019 Jul; 96(1):8-10. PubMed ID: 31229049
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
    Farmer AJ; Stevens R; Hirst J; Lung T; Oke J; Clarke P; Glasziou P; Neil A; Dunger D; M Colhoun H; Pugh C; Wong G; Perera R; Shine B
    Health Technol Assess; 2014 Feb; 18(14):1-128. PubMed ID: 24576414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease.
    Yamanouchi M; Mori M; Hoshino J; Kinowaki K; Fujii T; Ohashi K; Furuichi K; Wada T; Ubara Y
    BMJ Open Diabetes Res Care; 2019; 7(1):e000726. PubMed ID: 31798893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes and the kidney.
    O'Connor AS; Schelling JR
    Am J Kidney Dis; 2005 Oct; 46(4):766-73. PubMed ID: 16183435
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of exercise training on diabetic kidney disease: A brief physiological approach.
    Amaral LSB; Souza CS; Lima HN; Soares TJ
    Exp Biol Med (Maywood); 2020 Jul; 245(13):1142-1154. PubMed ID: 32486850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
    Toto RD
    Nephron; 2017; 137(1):64-67. PubMed ID: 28743130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".
    Pugliese G; Penno G; Natali A; Barutta F; Di Paolo S; Reboldi G; Gesualdo L; De Nicola L;
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1127-1150. PubMed ID: 31586514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes.
    Imafuku T; Watanabe H; Oniki K; Yoshida A; Kato H; Nakano T; Tokumaru K; Fujita I; Arimura N; Maeda H; Sakamoto Y; Kondo N; Morita A; Saruwatari J; Tanaka M; Matsushita K; Wada T; Fukagawa M; Otagiri M; Fitzgerald ML; Jinnouchi H; Maruyama T
    Diabetes Care; 2021 Jun; 44(6):e115-e117. PubMed ID: 33905348
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel biomarkers for prognosticating diabetic kidney disease progression.
    Swaminathan SM; Rao IR; Shenoy SV; Prabhu AR; Mohan PB; Rangaswamy D; Bhojaraja MV; Nagri SK; Nagaraju SP
    Int Urol Nephrol; 2023 Apr; 55(4):913-928. PubMed ID: 36271990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glycosaminoglycans in diabetic nephropathy].
    Olszowska A
    Pol Merkur Lekarski; 2000 Dec; 9(54):873-5. PubMed ID: 11255659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.